Tobacco Assays
| Assay | Exposure Component/Indication | Measured Analyte | Methos of Analysis | LLOQ | Matrix |
|---|---|---|---|---|---|
| Trace Nicotine | Nicotine | Nicotine | LC-MS/MS | 0.200 ng/mL | Plasma (K₂EDTA) |
| Nicotine | Cotinine | LC-MS/MS | 1.00 ng/mL | Plasma (K₂EDTA) | |
| Nicotine | 𝑡𝑟𝑎𝑛𝑠-3’-hydroxycotinine | LC-MS/MS | 1.00 ng/mL | Plasma (K₂EDTA) | |
| Trace Nicotine | Nicotine | Nicotine | LC-MS/MS | 0.200 ng/mL | Plasma (Heparin) |
| Nicotine | Cotinine | LC-MS/MS | 1.00 ng/mL | Plasma (Heparin) | |
| Nicotine | 𝑡𝑟𝑎𝑛𝑠-3’-hydroxycotinine | LC-MS/MS | 1.00 ng/mL | Plasma (Heparin) | |
| Nicotine | Nicotine | Nicotine | LC-MS/MS | 0.500 ng/mL | Serum |
| Nicotine | Cotinine | LC-MS/MS | 1.00 ng/mL | Serum |
Exposure Marker Assays
| Assay | Exposure Component/Indication | Measured Analyte | Methos of Analysis | LLOQ | Matrix |
|---|---|---|---|---|---|
| Total 1-OHP | Pyrene | 1-Hydroxypyrene | LC-MS/MS | 10.0 pg/mL | Urine |
| Total 3-OH BaP | Benzo[a]pyrene | 3-Hydroxybenzo[a]pyrene | LC-MS/MS | 25.0 fg/mL | Urine |
| Meracapturic Acids | Acrolein | 3-Hydroxypropylmercapturic Acid (3-HPMA) | LC-MS/MS | 10.0 ng/mL | Urine |
| Acrolein | 2-HydroxypropylmercapturicAcid (2-HPMA) | LC-MS/MS | 2.50 ng/mL | Urine | |
| Crotonaldehyde | 3-Hydroxy-1-methylpropylmercapturic Acid (HMPMA) | LC-MS/MS | 10.0 ng/mL | Urine | |
| Acrylonitrile | 2-cyanoethyl-mercapruric acid (CEMA) | LC-MS/MS | 0.250 ng/mL | Urine | |
| MHBMA | 1,3-Butadiene | Monohydroxybutenylmercapturic Acid | LC-MS/MS | 100 pg/mL | Urine |
| Nicotine Equivalents | Nicotine | Nicotine | LC-MS/MS | 10.0 ng/mL | Urine |
| Nicotine | Cotinine | LC-MS/MS | 10.0 ng/mL | Urine | |
| Nicotine | 𝑡𝑟𝑎𝑛𝑠-3’-hydroxycotinine | LC-MS/MS | 10.0 ng/mL | Urine | |
| Nicotine | Nicotine-𝑁-glucuronide | LC-MS/MS | 10.0 ng/mL | Urine | |
| Nicotine | Cotinine-𝑁-glucuronide | LC-MS/MS | 20.0 ng/mL | Urine | |
| Nicotine | trans-3’-hydroxycotinine-O-glucuronide | LC-MS/MS | 50.0 ng/mL | Urine | |
| Nicotine Equivalents | Nicotine | Nicotine | LC-MS/MS | 50.0 ng/mL | Urine |
| Nicotine | Cotinine | LC-MS/MS | 50.0 ng/mL | Urine | |
| Nicotine | 𝑡𝑟𝑎𝑛𝑠-3’-hydroxycotinine | LC-MS/MS | 50.0 ng/mL | Urine | |
| Nicotine | Nicotine-𝑁-glucuronide | LC-MS/MS | 50.0 ng/mL | Urine | |
| Nicotine | Cotinine-𝑁-glucuronide | LC-MS/MS | 200 ng/mL | Urine | |
| Nicotine | 𝑡𝑟𝑎𝑛𝑠-3’-hydroxycotinine-O-glucuronide | LC-MS/MS | 200 ng/mL | Urine | |
| Total NNAL | Tobacco specific nitrosamines | 4-(Methylnitrosamino)-1-(3-pyridyl) -1-butanol | LC-MS/MS | 5.00 pg/mL | Urine |
| Total NNN | Tobacco specific nitrosamines | 𝑁-Nitrosonornicotine | LC-MS/MS | 0.200 pg/mL | Urine |
| Total NAT/NAB | Tobacco specific nitrosamines | 𝑁-Nitrosanabasine | LC-MS/MS | 2.00 pg/mL | Urine |
| Tobacco specific nitrosamines | 𝑁-Nitrosanatabine | LC-MS/MS | 5.00 pg/mL | Urine | |
| S-PMA | Benzene | S-Phenyl mercapuric acid | LC-MS/MS | 25.0 pg/mL | Urine |
| HEMA | Ethylene dioxide | Hydroxyethyl mercapturic acid | LC-MS/MS | 0.1 ng/mL | Urine |
| o-Toluidine | o-Toluidine | o-Toluidine | LC-MS/MS | 20 pg/mL | Urine |
| Aromatic Amines | Aromatic Amines | 1-Aminonaphthalene (1-NA) | LC-MS/MS | 2.0 pg/mL | Urine |
| Aromatic Amines | 2-Aminonaphthalene (2-NA) | LC-MS/MS | 2.0 pg/mL | Urine | |
| Aromatic Amines | 3-Aminobiphenyl (3-ABP) | LC-MS/MS | 0.500 pg/mL | Urine | |
| Aromatic Amines | 4-Aminobiphenyl (4-ABP) | LC-MS/MS | 1.0 pg/mL | Urine | |
| Propelyne Glycol | Propelyne Glycol | Propelyne Glycol | LC-MS/MS | 250 ng/mL | Urine |
| CoHb (Carboxyhemoglobin) | Carbon monoxide | COHb | Spectrophotometric | 0.50% | Whole Blood |
Biosimilar Assays
| Assay | Exposure Component/Indication | Measured Analyte | Methos of Analysis | LLOQ | Matrix |
|---|---|---|---|---|---|
| 11-dTXB2 | Platelet activation | 11-dehydro Thromboxane B₂ | LC-MS/MS | 25.00 pg/mL | Urine |
| iPF2a-III | Oxidative stress | Isoprostaglandin F₂ₐ (type III) | LC-MS/MS | 25.0 pg/mL | Urine |
| iPF2a-VI | Oxidative stress | Isoprostaglandin F₂ₐ (type VI) | LC-MS/MS | 25.0 pg/mL | Urine |
| Creatinine | Kidney Function | Creatinine | LC-MS/MS | 50.0 µg/mL | Urine |
| 2,3 dinor Thromboxane-B2 (TXB2) | Platelet activation | 2,3 dinor Thromboxane-B₂ (TXB₂) | LC-MS/MS | 25.0 pg/mL | Urine |
| sICAM | Systemic inflamatory reponse | sICAM | ELISA | 12.5 ng/mL | Plasma |
| Malondialdehyde | Lipid peroxidation | Malondialdehyde | EIA | 20.0 ng/mL | K₂EDTA |
| IL-6 | Cytokine, inflamatory marker | IL-6 | ELISA | 3.12 pg/mL | Serum |
| TNFa | Inflammatory reponse | Tumor ncrosis factor alpha | EIA | 1.00 pg/mL | Li Hep Plasma |
| high sensitivity C-reactive protein | Atherosclerotic cardiovascular disease | hsCRP | Clinical Laboratory | 0.25 mg/L | Serum |
| Fibrinogen | Chronic COPD | Fibrinogen | Clinical Laboratory | 63 mg/dL | Na Citrate Plasma |
| IL-6. IL-8, TNFa | Panel assay of inflammation biomarkers | IL-6, IL-8, TNFa | MSD Panel | Li Hep Plasma | |
| Matrix Metalloproteinase-9 | Tumor formation | Metalloproteinase-9 | ELISA | Serum | |
| Surfactant Protein D | COPD development | Surfactant Protein D | ELISA | Serum | |
| MCP-1 | Cytokine, inflammatory marker | Monocyte chemoattractant protein-1 | ELISA | 40.0 pg/mL | Serum |